

ASX Announcement

Racura to Host New Zealand Investor Briefing in Auckland & Present at the 20th Bioshares Biotech Summit

6 July 2026

Racura Oncology Limited (“Racura” or the “Company”) wishes to remind investors that it will be hosting an investor briefing in Auckland, New Zealand, on 5 August 2026, with all existing and potential shareholders invited to attend. Racura is also pleased to announce that Executive Chair Dr Peter Smith will present at the upcoming 20th Bioshares Biotech Summit in Queenstown, New Zealand, on 6–7 August 2026.

Auckland Briefing

Executive Chair Dr Peter Smith will host a morning tea briefing for investors, outlining Racura’s strategy and the rapid advancement of RC220 through a broad clinical development program spanning three major oncology indications.

The briefing will provide updates on the Company’s Phase 3 AML program for RC220 targeting c-MYC silencing, the HARNESS-1 Phase 1 trial of RC220 with Tagrisso® in EGFR-mutant NSCLC, and the CPACS trial assessing RC220 with doxorubicin as a cardioprotective anticancer treatment. Dr Smith will also outline the Company’s near-term catalyst schedule.

Date	Wednesday, 5 August, 2026
Time	10:15AM for a 10:30AM start
Location	Central Auckland location to be confirmed closer to the date
RSVP	Places are limited so please register your RSVP by Friday, 10 July 2026 via racura@irdepartment.com.au

Bioshares Biotech Summit

Dr Peter Smith will participate in the 20th *Bioshares Biotech Summit* in Queenstown, New Zealand, on 6 and 7 August 2026. He will present on Racura Oncology at 12:15PM on Friday, 7 August 2026, and chair Session 4: Improving Lifespan from 4:30PM to 5:45PM on Thursday, 6 August 2026.

For more information about the *Bioshares Biotech Summit* or to register for the conference, please visit the [Bioshares website](#). Investors interested in arranging a meeting during the *Bioshares Summit* may contact Jane Lowe at jane.lowe@irdepartment.com.au.

-ENDS-

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provides for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements, please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au